Berlin’s Diagnostisch Therapeutisches Zentrum (DTZ) has become the first in the world to treat a patient using Elekta Evo, an ...

Bayer’s initiative reflects a broader effort to address the high unmet medical need in oncology. The trial’s success could ...

Beckley Psytech has announced positive topline results from its phase 2a study of ELE-101, a synthetic intravenous (IV) ...

Global biotechnology leader CSL has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for ...

Minoryx Therapeutics and Neuraxpharm Group have announced that leriglitazone has met the primary endpoint in the NEXUS trial ...

CatalYm has announced promising new data on its lead drug candidate, visugromab, at the 17th International Conference on ...

Patients don’t take their medicines because they don’t want to Debra is late getting up for work again. In her heart of ...

MindMed has announced the dosing of the first patient in its phase 3 Voyage study of MM120 ODT, a pharmaceutically optimised form of lysergide D-tartrate (LSD) for treating Generalised Anxiety ...

PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative ...

iOnctura has announced promising results from the phase 1 DIONE-01 study, showcasing the clinical activity and long-term ...